Current status and challenges of TCR-T therapy in solid tumor

VernacularTitle:实体肿瘤TCR-T治疗研究的现状与面临的挑战
Author: YE Chunmei ^{1
,

2
,

3} ; YE Yunbin ^{1
,

2
,

3}
Author Information

1. The School of Basic Medical Science, Fujian Medical University;
2. Cancer Hospital of Fujian Medical University & Fujian Provincial Cancer Hospital;
3. Key Laboratory of Translational Cancer Medicine of Fujian Province，Fuzhou 350014, Fujian, China
Publication Type:Journal Article
Keywords: solid tumor; adoptive cellular immunotherapy; TCR-engineered T cells (TCR-T); neoantigen
From: Chinese Journal of Cancer Biotherapy 2020;27(9):959-967
CountryChina
Language:Chinese
Abstract: [Abstract] T cell receptors (TCR) are specifically expressed on T cell surface, which can recognize different tumor antigens to kill and scavenge cancerous cells. TCR-engineered T cells (TCR-T) therapy is to harbor TCR specific to tumor cells and modify the T cells with genetic engineering techniques to achieve the purpose of treating tumors after transfusion. Despite some achievements in TCR-T therapy, there are still some problems, such as treatment toxicity, limited T cell infiltration and antigen-specific deficiency and so on. So, the safety and effectiveness of TCR-T therapy need to be constantly optimized. Therefore，this paper summarizes the research status of TCR-T therapy for solid tumors in domestic and overseas, as well as the existing problems and countermeasures.
Full text:20200901.pdf